Undecimal Bio, a biotechnology startup advancing targeted delivery of siRNA therapeutics, has raised US$18 million in a Seed funding round.
The seed round was co-led by 4BIO Capital and IQ Capital, with participation from Verve Ventures, Harel Tech, Entree Capital, Kerna Ventures and Saras Capital.
The startup, a spin-out from Eleven Therapeutics, plans to use the Seed funding to expand DELiveri, its proprietary AI-enabled platform for identifying conjugates that can direct RNA medicines to defined cell types, addressing a major constraint in genetic medicine delivery.
Undecimal is initially applying the DELiveri platform in renovascular diseases, which pose significant unmet clinical need. Existing treatments of these indications largely address symptoms rather than the underlying etiological factors. Targeted siRNA delivery holds the potential to bring the digital-like precision of genetic medicines, enabling durable, target-specific silencing of the disease-driving pathways.
Undecimal has entered several research collaborations with big pharma companies, which are yet to be disclosed.